Gastroenterology Podcast January 2012: Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy Following Infliximab Therapy
A study in the January issue of Gastroenterology sought to determine whether infliximab therapy can be safely interrupted in patients with Crohn's disease who have undergone a period of prolonged remission. The authors assessed the risk of relapse after infliximab therapy was discontinued in patients on combined maintenance therapy with antimetabolites and identified factors associated with relapse Dr. Kuemmerle speaks to first author Prof. Edouard Louis of the Centre Hospitalier Universitaire de Liège, Liège, Belgium; Plus, a rundown of top stories from this month's issue of GI and Hepatology News.
Louis E, Mary JY, Vernier–Massouille G. Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped. Gastroenterology 2012; Jan; 142(1): 63-70
Abstract
Duration: 16.05
Filetype: mp3
Bitrate: 96 KBPS
Frequency: 44100 HZ
Download: /attachments/gastroenterology_podcast_january_2012.mp3
